Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma.

Feingold PL, Surman DR, Brown K, Xu Y, McDuffie LA, Shukla V, Reardon ES, Crooks DR, Trepel JB, Lee S, Lee MJ, Gao S, Xi S, McLoughlin KC, Diggs LP, Beer DG, Nancarrow DJ, Neckers LM, Davis JL, Hoang CD, Hernandez JM, Schrump DS, Ripley RT.

Mol Cancer Ther. 2018 Sep;17(9):2013-2023. doi: 10.1158/1535-7163.MCT-17-1240. Epub 2018 Jun 22.

2.

Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy.

Taylor Ripley R, Surman DR, Diggs LP, Trepel JB, Lee MJ, Ryan J, Davis JL, Steinberg SM, Hernandez JM, Hoang C, Kenney CM, Bond CD, Kunst TF, Letai A, Schrump DS.

BMC Gastroenterol. 2018 Jun 22;18(1):94. doi: 10.1186/s12876-018-0823-x.

3.

Bile acid and cigarette smoke enhance the aggressive phenotype of esophageal adenocarcinoma cells by downregulation of the mitochondrial uncoupling protein-2.

Xu Y, Feingold PL, Surman DR, Brown K, Xi S, Davis JL, Hernandez J, Schrump DS, Ripley RT.

Oncotarget. 2017 Nov 10;8(60):101057-101071. doi: 10.18632/oncotarget.22380. eCollection 2017 Nov 24.

4.

Deletion of Mthfd1l causes embryonic lethality and neural tube and craniofacial defects in mice.

Momb J, Lewandowski JP, Bryant JD, Fitch R, Surman DR, Vokes SA, Appling DR.

Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):549-54. doi: 10.1073/pnas.1211199110. Epub 2012 Dec 24.

5.

CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.

Gattinoni L, Ranganathan A, Surman DR, Palmer DC, Antony PA, Theoret MR, Heimann DM, Rosenberg SA, Restifo NP.

Blood. 2006 Dec 1;108(12):3818-23. Epub 2006 Aug 1.

6.

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, Rosenberg SA, Restifo NP.

J Immunol. 2005 Mar 1;174(5):2591-601.

7.

Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance.

Yu Z, Theoret MR, Touloukian CE, Surman DR, Garman SC, Feigenbaum L, Baxter TK, Baker BM, Restifo NP.

J Clin Invest. 2004 Aug;114(4):551-9.

8.

Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer.

Finkelstein SE, Heimann DM, Klebanoff CA, Antony PA, Gattinoni L, Hinrichs CS, Hwang LN, Palmer DC, Spiess PJ, Surman DR, Wrzesiniski C, Yu Z, Rosenberg SA, Restifo NP.

J Leukoc Biol. 2004 Aug;76(2):333-7. Epub 2004 May 20.

9.

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.

Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, Tagaya Y, Rosenberg SA, Waldmann TA, Restifo NP.

Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1969-74. Epub 2004 Feb 4.

10.

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP.

J Exp Med. 2003 Aug 18;198(4):569-80.

11.

Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo.

Bronte V, Apolloni E, Ronca R, Zamboni P, Overwijk WW, Surman DR, Restifo NP, Zanovello P.

Cancer Res. 2000 Jan 15;60(2):253-8.

12.

Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.

Surman DR, Dudley ME, Overwijk WW, Restifo NP.

J Immunol. 2000 Jan 15;164(2):562-5.

13.

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP.

Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2982-7.

14.

Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen.

Carroll MW, Overwijk WW, Surman DR, Tsung K, Moss B, Restifo NP.

J Natl Cancer Inst. 1998 Dec 16;90(24):1881-7.

15.

Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.

Bronte V, Wang M, Overwijk WW, Surman DR, Pericle F, Rosenberg SA, Restifo NP.

J Immunol. 1998 Nov 15;161(10):5313-20.

16.

Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer.

Restifo NP, Surman DR, Zheng H, Palese P, Rosenberg SA, GarcĂ­a-Sastre A.

Virology. 1998 Sep 15;249(1):89-97.

17.

Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization.

Surman DR, Irvine KR, Shulman EP, Allweis TM, Rosenberg SA, Restifo NP.

J Immunol Methods. 1998 May 1;214(1-2):51-62.

18.

Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors.

Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP.

J Natl Cancer Inst. 1997 Nov 5;89(21):1595-601.

PMID:
9362157
19.

Cyclin-dependent kinase activation and S-phase induction of the cyclin B1 gene are linked through the CCAAT elements.

Katula KS, Wright KL, Paul H, Surman DR, Nuckolls FJ, Smith JW, Ting JP, Yates J, Cogswell JP.

Cell Growth Differ. 1997 Jul;8(7):811-20.

20.

Supplemental Content

Loading ...
Support Center